Evidence map›Paper›PMID 29262598›Full record

ArticleOncotarget2017

Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model.

Hayley C Affronti, Mark D Long, Spencer R Rosario, Bryan M Gillard, Ellen Karasik, Christoph S Boerlin, Anthony J Pellerite, Barbara A Foster, Kristopher Attwood, Roberto Pili and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Scientific opinion on the tolerable upper intake level for folate.EFSA journal. European Food Safety Authority · 2023
    Article
  3. Review
  4. Nucleosome destabilization by polyamines.Archives of biochemistry and biophysics · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Hayley C AffrontiDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Mark D LongDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Spencer R RosarioDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Bryan M GillardDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Ellen KarasikDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Christoph S BoerlinDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Anthony J PelleriteDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Barbara A FosterDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Kristopher AttwoodDepartment of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Roberto PiliDepartment of Hematology and Oncology, Indiana University, Indianapolis, IN, USA.
John H WiltonDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Moray J CampbellCollege of Pharmacy, Pharmaceutics and Pharmaceutical Chemistry, The Ohio State University, Columbus, OH, USA.
Dominic J SmiragliaDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Roswell Park Comprehensive Cancer Center · USIndiana University – Purdue University Indianapolis · USThe Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.R01CA197996 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI SMIRAGLIA, DOMINIC JAMES · 2016 to 2020
$2.1M
Dietary Folate: Impact on Prostate Tumor Biology, Genetics and EpigeneticsR21CA131646 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI SMIRAGLIA, DOMINIC JAMES · 2009 to 2010
$440k
Leveraging polyamine metabolic stress as a novel therapy for prostate cancerF99CA212455 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AFFRONTI, HAYLEY · 2016 to 2017
$60k
NCI NIH HHS F99 CA212455NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA197996NCI NIH HHS R21 CA131646
6 · The paper itself

Abstract

Folate impacts the genome and epigenome by feeding into one-carbon metabolism to produce critical metabolites, deoxythymidine monophosphate and s-adenosylmethionine. The impact of folate exposure and intervention timing on cancer progression remains controversial. Due to polyamine metabolism's extraordinary biosynthetic flux in prostate cancer (CaP) we demonstrated androgen stimulated CaP is susceptible to dietary folate deficiency. We hypothesized dietary folate levels may also affect castration recurrent CaP. We used the CWR22 human xenograft model which recurs following androgen withdrawal. Engrafted mice were fed a folate depleted or supplemented diet beginning at androgen withdrawal, or prior to xenograft implantation. Both folate depletion and supplementation at the time of withdrawal significantly decreased recurrence incidence. Folate supplementation prior to xenograft implantation increased time to recurrence, suggesting a protective role. By contrast, folate depleted recurrent tumors exhibited transcriptional adaptive responses that maintained high polyamine levels at the expense of increased DNA damage and DNA methylation alterations. Mining of publically available data demonstrated folate related pathways are exceptionally dysregulated in human CaP, which correlated with decreased time to biochemical recurrence. These findings highlight the potential for novel therapeutic interventions that target these metabolic pathways in CaP and provide a rationale to apply such strategies alongside androgen withdrawal.

Indexed as

androgen withdrawalcastration recurrent prostate cancerfolateone-carbon metabolismpolyamine metabolism

Identifiers

PMID29262598
PMCPMC5732764
OpenAlexW2766204818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.